Literature DB >> 20061625

Altered distribution of RhoA in Alzheimer's disease and AbetaPP overexpressing mice.

Gema Huesa1, María Antonia Baltrons, Pilar Gómez-Ramos, Asunción Morán, Agustina García, Juan Hidalgo, Silvia Francés, Gabriel Santpere, Isidre Ferrer, Elena Galea.   

Abstract

RhoGTPases control cytoskeleton dynamics thereby modulating synaptic plasticity. Because Alzheimer's disease (AD) is characterized by synaptic dysfunction, we sought to determine whether the expression, activity, or localization of the GTPases RhoA, Rac1 and Cdc42, as well as p21-PAK, a downstream target of Rac1/Cdc42, were altered in 18-month-old AbetaPP Tg2576 mice (Swedish mutation) or in brains from patients with AD and, for comparison in the case of RhoA, Pick's disease (PiD), a neurodegenerative disorder characterized by hyper-phosphorylated tau accumulation. Immunohistochemical analyses revealed a distinct localization of each RhoGTPase in synapses, dendrite shafts, neuronal bodies, or astrocytes. The association of RhoA with synapses and dendritic microtubules was confirmed by electron microscopy. In AbetaPP mice, RhoA expression decreased in synapses and increased in dystrophic neurites, suggesting altered subcellular targeting of RhoA. In AD, RhoA immunostaining decreased in the neuropil and markedly increased in neurons, co-localizing with hyperphosphorylated tau inclusions, as though RhoA were sequestered by neurofibrillary tangles. Additionally, total RhoA protein was lower in the AD brain hippocampus, reflecting loss of the membrane bound, presumably active, GTPase. RhoA colocalized with hyperphosphorylated tau in PiD, again suggesting that altered subcellular targeting of RhoA is related to neurodegeneration. No major immunohistochemical changes were observed for Rac1, Cdc42, or p21-PAK, thus identifying RhoA among RhoGTPases as a possible therapeutic target in AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061625     DOI: 10.3233/JAD-2010-1203

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  40 in total

1.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

Review 2.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease.

Authors:  Peter Penzes; Jon-Eric Vanleeuwen
Journal:  Brain Res Rev       Date:  2011-01-26

3.  Pyk2 Signaling through Graf1 and RhoA GTPase Is Required for Amyloid-β Oligomer-Triggered Synapse Loss.

Authors:  Suho Lee; Santiago V Salazar; Timothy O Cox; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

4.  Nonsteroidal anti-inflammatory drugs attenuate amyloid-β protein-induced actin cytoskeletal reorganization through Rho signaling modulation.

Authors:  Patricia Ferrera; Angélica Zepeda; Clorinda Arias
Journal:  Cell Mol Neurobiol       Date:  2017-01-25       Impact factor: 5.046

5.  Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer's Disease.

Authors:  Jonas Folke; Bente Pakkenberg; Tomasz Brudek
Journal:  Mol Neurobiol       Date:  2018-05-26       Impact factor: 5.590

Review 6.  The potential role of rho GTPases in Alzheimer's disease pathogenesis.

Authors:  Silvia Bolognin; Erika Lorenzetto; Giovanni Diana; Mario Buffelli
Journal:  Mol Neurobiol       Date:  2014-01-23       Impact factor: 5.590

Review 7.  Reversing synapse loss in Alzheimer's disease: Rho-guanosine triphosphatases and insights from other brain disorders.

Authors:  Roger Lefort
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 8.  Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease.

Authors:  Ana Gabriela Henriques; Joana Machado Oliveira; Liliana Patrícia Carvalho; Odete A B da Cruz E Silva
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 9.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

10.  Endocytic pathways mediating oligomeric Abeta42 neurotoxicity.

Authors:  Chunjiang Yu; Evelyn Nwabuisi-Heath; Kevin Laxton; Mary Jo Ladu
Journal:  Mol Neurodegener       Date:  2010-05-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.